Pioneering cancer scientist Judah Folkman dies

Dr. Judah Folkman (photo)--whose work on angiogenesis spawned a new category of oncology drugs--died on Monday at the age of 74. His groundbreaking research demonstrating tumors' need for growing numbers of blood vessels led to the development of 10 cancer drugs on the market today and spawned a wide array of follow-up investigations that continue to drive experiments into new cancer treatments. While not a cure for cancer, observers note that Folkman pointed the way to make many cancers a manageable chronic disease. The New York Times notes that deep skepticism greeted Folkman's initial work, but a 1998 study showing how the process eliminated tumors in mice stirred a frenzy of interest.

"I think he was one of the most important investigators of our time," Dr. David Nathan, president emeritus of the Dana-Farber Cancer Institute in Boston, told the Wall Street Journal. "Losing him is like watching a Roman candle go out."

- read the report from the Wall Street Journal
- and here's the article from The New York Times

Suggested Articles

The CTAD presentation cleared up some questions about the dataset without delivering a telling blow for either side of the debate.

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.